l ''Lab.med, 8:1-4 (1984)
Zur Bedeutung von Alpha-Fetoprotein (AFP)
und Choriongonadotropin (Beta-HCG)
bei malignen Hodengeschwülsten - urologische
Aspekte für die routinemäßige Bestimmung
W. Weidner1, H. W. Bauer2, H. Bleyl3
1 Urologische Universitätsklinik Gießen,2 Urologische Universitätsklinik München,
3 Institut für Klinische Chemie der JL-Universität Gießen
Die Bestimmung von AFP und Beta-HCG im Serum bei malignen Hodentumoren wird erörtert Kriterien für die
Bewertung von erhöht gemessenen Werten werden aus urologischer Sicht in ihrer
). Hepatoblastoma (HB) is the most common liver malignancy in children and accounts for approximately 1% of childhood cancers (5). Surgery is necessary to achieve cure, but the role of chemotherapy in both neoadjuvant and adjuvant settings has become increasingly important over the past three decades (5). Typically, this tumor is associated with the secretion of alpha-fetoprotein (AFP), and most rarely, β-human chorionic gonadotropin (β-hCG) hormone, both representing useful biomarkers for disease monitoring and follow-up (6). Case report An 18-month-old male came to the
The feasibility of transcatheter arterial chemoembolization (TACE) combined with intratumoral injection of cisplatin as treatment for hepatocellular carcinoma. 30 cases receiving TACE were denoted the TACE group, another 30 cases receiving TACE combined with an intratumoral multi-point injection of cisplatin were denoted the TACE/cisplatin group. Cases with partial remission/complete remission (PR/CR) were analyzed using 2 tests; alpha fetoprotein (AFP), aspartate amino transferase (AST), total bilirubin (TBIL), erythrocyte, and platelet levels were detected and the differences between two groups were analyzed using the Student’s t-test; cases with complications, including intrahepatic metastasis (IM), upper gastrointestinal bleeding (UGB), and liver failure were also counted. The correlation of clinical parameters with PR/CR was analyzed using multifactorial correlation analysis. Cases with PR/CR in the TACE/cisplatin group were significantly more than in TACE group, accompanied by significant declination in FAP. There were no significant differences of AST, ALT, TBIL, blood urea nitrogen (BUN), white blood cells (WBC), red blood cells (RBC), and platelets (PLT) between two groups; 3 cases with IM, one case with UGB and one case with LF were found in the TACE group, but only 1 case with IM was found in the TACE/cisplatin group. In addition, tumor stage was correlated with PR/CR. We concluded that TACE combined with intratumoral injection of cisplatin was more effective than TACE, and with fewer complications and side effects.
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer associated death globally. Serum micro RNAs are full of potential as noninvasive biomarkers. Here, we aim to assess the performance of serum MicroRNA-155 and MicroRNA-665 as diagnostic biomarker for HCC comparing to AFP.
Serum samples were collected from 200 subjects (40 healthy control, 80 chronic hepatitis C patients with cirrhosis and without HCC (LC) and 80 HCC patients currently infected by hepatitis C infection and didn’t start the treatment). The HCC patients didn’t include alcoholic liver disease, nonalcoholic fatty liver disease nor autoimmune liver disease. MicroRNA-155 and MicroRNA-665 expression were measured by real-time quantitative PCR (RT-qPCR), while AFP level was assessed by ELISA method.
Both miR-155 and miR-665 were significantly elevated in HCC group as compared to both control and LC groups. The comparison between LC and HCC patients revealed that the serum level of miR-155 was a significant increase in HCC patients compared to LC patients; however, the serum level of miR-665 didn’t show any significant difference between the same two groups. MiR-665 expression level showed a direct correlation with tumor size in HCC patients.
Using measurement against AFP level in serum, miR-665 is considered a promising serum biomarker for the diagnosis of HCC patients among the LC patients without HCC. MiR-155 didn’t provide a better performance than serum AFP as a diagnostic biomarker among the same group. MiR-665 may serve as a good indicator for HCC prognosis.
diagnosis and treatment of the disease [ 4 ]. Tumor markers are potential screening tools used for early diagnosis of malignancies. Thus, determination of a suitable marker is clinically significant to the early diagnosis of PHC. Alphafetoprotein (AFP) is the most commonly used serum indicator for the auxiliary diagnosis of PHC [ 5 - 7 ]. Serum AFP level is related to tumor diameter, tumor differentiation, and biological characteristics. However, the AFP level of some patients remains normal in the early or even later period of PHC, whereas some patients with benign
Tsuda Y. ei al.: Serum Neopterin in HCC 161
Vol. 15, 2004, pp. 161 - 169
Serum Neopterin as a Marker for Screening of Hepatocellular Carcinoma
Yasuhiro Tsuda, Akira Fukuda , Hiroyuki Kobayashi , Dai Itou, Sa tomine Yoshimoto, Kazunari Iwata,
Toshiaki Hana fusa
First Depar tment of Internal Medicine , Osaka Medical College, Digakucho 2-7, Takatsuki,
Osaka 569-8686, Japan
As Screening markers for hepatocel lular Carcinoma (HCC), alpha-fetoprotein (AFP) and protein induced by an
absence of vi tamin K or antagonist-II (PIVKA-II ) are
significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol. 2004;99(5):860-5. 44. Yen YH, Changchien CS, Wang JH, Kee KM, Hung CH, Hu TH, et al. A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients. Dig Liver Dis. 2009;41(6):431-41. 45. Ueland J, Yuan A, Marlier A, Gallagher AR, Karihaloo A. A novel role for the chemokine receptor cxcr4 in kidney morphogenesis: an in vitro study. Dev
Early diagnosis of hepatocellular carcinoma (HCC) greatly improves the survival and prognosisfor patients. In this study weevaluate the diagnostic promise of combining serum alpha-fetoprotein (AFP) expression with two potential biomarkers, serum glypican-3 (GPC3) and expression of the micro-RNA miR-122 for hepatitis C virus (HCV) related early-stage HCC. For this study serum samples from 47 patients with early-stage HCC, 54 chronic HCV (CH) carriers, 35 patients with liver cirrhosis (LC) and 54 health controls (HC) were collected. In addition to routine laboratory investigations, serum AFP, GPC3 and miR-122 were measured in all patients and healthy controls. Receiver operating characteristic (ROC) curves were used to present sensitivity and specificity for the biomarkers. The three markers were all significantly elevated in the serum samples from HCC patients. ROC curves showed the three markers had similar diagnostic capacities for distinguishing early-stage HCC from HCV-positive controls (LC + CH). In order to distinguish early-stage HCC from high-risk LC patients, the expression of miR-122 was superior to GPC3. Combination of the three markers as a panel showed a better diagnostic performance than any of the single markers (P <0.05). Overall, this study revealed that serum expression of GPC3 and miR-122 may be useful biomarkers to combine with serum AFP expression for the diagnosis of HCV related early-stage HCC.